Publication details

Iron chelators as mitophagy agents: Potential and limitations

Investor logo
Investor logo
Investor logo
Authors

BROGYANYI Tereza KEJIK Zdenek VESELA Katerina DYTRYCH Petr HOSKOVEC David MASAŘÍK Michal BABULA Petr KAPLANEK Robert PRIBYL Tomas ZELENKA Jaroslav RUML Tomas VOKURKA Martin MARTASEK Pavel JAKUBEK Milan

Year of publication 2024
Type Article in Periodical
Magazine / Source BIOMEDICINE & PHARMACOTHERAPY
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/pii/S0753332224012927?via%3Dihub
Doi http://dx.doi.org/10.1016/j.biopha.2024.117407
Keywords Mitophagy; Iron heomeostais; Iron chelators; Cancer; Neurodegenerative diseases; Cardiovascular diseases
Attached files
Description Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info